CA3016491A1 - Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists - Google Patents
Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists Download PDFInfo
- Publication number
- CA3016491A1 CA3016491A1 CA3016491A CA3016491A CA3016491A1 CA 3016491 A1 CA3016491 A1 CA 3016491A1 CA 3016491 A CA3016491 A CA 3016491A CA 3016491 A CA3016491 A CA 3016491A CA 3016491 A1 CA3016491 A1 CA 3016491A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- group
- compounds
- iii
- cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 | |
| US62/310,409 | 2016-03-18 | ||
| PCT/US2017/023206 WO2017161370A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3016491A1 true CA3016491A1 (en) | 2017-09-21 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3016491A Pending CA3016491A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10906909B2 (https=) |
| EP (2) | EP3439665B1 (https=) |
| JP (2) | JP7023876B2 (https=) |
| AU (2) | AU2017235665B2 (https=) |
| CA (1) | CA3016491A1 (https=) |
| CY (1) | CY1125576T1 (https=) |
| DK (1) | DK3439665T3 (https=) |
| ES (1) | ES2926918T3 (https=) |
| HR (1) | HRP20221098T1 (https=) |
| HU (1) | HUE059774T2 (https=) |
| LT (1) | LT3439665T (https=) |
| PL (1) | PL3439665T3 (https=) |
| PT (1) | PT3439665T (https=) |
| RS (1) | RS63674B1 (https=) |
| SI (1) | SI3439665T1 (https=) |
| SM (1) | SMT202200372T1 (https=) |
| WO (1) | WO2017161370A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7013446B2 (ja) | 2016-08-16 | 2022-02-15 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 |
| US20220105106A1 (en) * | 2019-02-13 | 2022-04-07 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| SG11202109526PA (en) * | 2019-03-18 | 2021-10-28 | Neurocycle Therapeutics Inc | Use of gabaa receptor modulators for treatment of pain |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| US20240374612A1 (en) * | 2021-09-08 | 2024-11-14 | Uwm Research Foundation, Inc. | Imidazobenzodiazepines for treatment of cognitive and mood symptoms |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| AU2022359461A1 (en) * | 2021-10-07 | 2024-05-02 | Pantherics Incorporated | Methods and compounds for treating inflammation |
| WO2024077061A2 (en) * | 2022-10-04 | 2024-04-11 | Uwm Research Foundation, Inc. | Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation |
| IT202400001089A1 (it) * | 2024-01-22 | 2025-07-22 | Fondazione St Italiano Tecnologia | Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) * | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| CA2570185A1 (en) | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| WO2007042544A2 (en) | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gabaa receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| EP2364571B1 (en) | 2008-10-02 | 2012-08-22 | Telefonaktiebolaget L M Ericsson (PUBL) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| CA2979701C (en) | 2015-03-20 | 2023-01-03 | Uwm Research Foundation, Inc. | Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands |
-
2017
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en not_active Ceased
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 SM SM20220372T patent/SMT202200372T1/it unknown
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP7515526B2/ja active Active
- 2022-09-27 CY CY20221100636T patent/CY1125576T1/el unknown
- 2022-11-23 AU AU2022275446A patent/AU2022275446B2/en active Active
-
2023
- 2023-08-02 US US18/363,933 patent/US12180216B2/en active Active
-
2024
- 2024-11-12 US US18/944,947 patent/US20250179080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3439665T (lt) | 2022-10-10 |
| PT3439665T (pt) | 2022-09-27 |
| US12180216B2 (en) | 2024-12-31 |
| HRP20221098T1 (hr) | 2022-11-25 |
| AU2017235665B2 (en) | 2022-12-08 |
| WO2017161370A1 (en) | 2017-09-21 |
| EP3439665A1 (en) | 2019-02-13 |
| DK3439665T3 (da) | 2022-09-26 |
| JP2019509340A (ja) | 2019-04-04 |
| AU2022275446B2 (en) | 2025-01-02 |
| RS63674B1 (sr) | 2022-11-30 |
| AU2022275446A1 (en) | 2023-01-05 |
| EP3439665A4 (en) | 2019-11-27 |
| JP2022065035A (ja) | 2022-04-26 |
| SMT202200372T1 (it) | 2022-11-18 |
| PL3439665T3 (pl) | 2023-01-16 |
| SI3439665T1 (sl) | 2023-05-31 |
| US11753412B2 (en) | 2023-09-12 |
| EP4129297A1 (en) | 2023-02-08 |
| EP3439665B1 (en) | 2022-06-29 |
| US20210309662A1 (en) | 2021-10-07 |
| JP7515526B2 (ja) | 2024-07-12 |
| ES2926918T3 (es) | 2022-10-31 |
| CY1125576T1 (el) | 2026-02-25 |
| US10906909B2 (en) | 2021-02-02 |
| US20200181146A1 (en) | 2020-06-11 |
| US20240083905A1 (en) | 2024-03-14 |
| WO2017161370A8 (en) | 2018-09-27 |
| HUE059774T2 (hu) | 2023-01-28 |
| JP7023876B2 (ja) | 2022-02-22 |
| US20250179080A1 (en) | 2025-06-05 |
| AU2017235665A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12180216B2 (en) | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists | |
| AU2021200164B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| KR100883003B1 (ko) | 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온 | |
| AU2014368961B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| AU2017393082B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| ES2942308T3 (es) | Compuestos y su uso como inhibidores de BACE1 | |
| AU2019288382B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| AU2015222805B2 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| US10889584B2 (en) | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | |
| US20190300534A1 (en) | Gabaergic ligands and their uses | |
| US20240374612A1 (en) | Imidazobenzodiazepines for treatment of cognitive and mood symptoms | |
| JP7738924B2 (ja) | 新規ｖｄａｃ１阻害剤 | |
| JP2020519647A (ja) | グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換複素環式化合物 | |
| Li | Design and synthesis of achiral and chiral imidazodiazepine (IMDZ) GABA (A) R subtype selective ligands for the treatment of CNS disorders, as well as Asthma | |
| OA19667A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220208 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250314 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250314 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250314 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250611 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250721 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250721 |